FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
466.79k
1.24M
9M
3.31M
6.59T
10.49T
16.7T
26.59T
42.33T
67.39T
Revenue %
-
166.01
625.17
-63.23
199.06M
59.19
59.19
59.19
59.19
Ebitda
-27.63M
-36.32M
-19.79M
-11.79M
-11.12T
-10.49T
-16.7T
-26.59T
-42.33T
-67.39T
Ebitda %
-5.92k
-2.92k
-219.79
-356.14
-168.69
-100
-100
-100
-100
Ebit
-28.71M
-39.48M
-23.47M
-14.58M
-4.53M
-8.39T
-13.36T
-21.27T
-33.86T
-53.91T
Ebit %
-6.15k
-3.18k
-260.66
-440.37
-0
-80
-80
-80
-80
Depreciation
1.08M
3.16M
3.68M
2.79M
-11.12T
4.72T
7.52T
11.97T
19.06T
30.34T
Depreciation %
230.44
254.7
40.87
84.23
-168.69
45.02
45.02
45.02
45.02
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
21.35M
42.35M
11.78M
15.11M
19.19T
10.49T
16.7T
26.59T
42.33T
67.39T
Total Cash %
4.57k
3.41k
130.85
456.38
291.19
100
100
100
100
Receivables
1M
237
2.4M
1.03M
2.35T
4.06T
6.46T
10.28T
16.37T
26.06T
Receivables %
214.35
0.02
26.68
31.04
35.6
38.67
38.67
38.67
38.67
Inventories
-1M
-
-
-988.13k
-
-2.72T
-4.34T
-6.91T
-10.99T
-17.5T
Inventories %
-214.23
-
-
-29.84
-
-25.97
-25.97
-25.97
-25.97
Payable
2.94M
5.14M
1.1M
961k
1.07M
5.06T
8.06T
12.83T
20.42T
32.51T
Payable %
628.77
414.27
12.23
29.02
0
48.25
48.25
48.25
48.25
Cap Ex
-10.43M
-3.13M
-4.95M
-
-
-5.35T
-8.52T
-13.56T
-21.58T
-34.36T
Cap Ex %
-2.23k
-252.16
-54.92
-
-
-50.98
-50.98
-50.98
-50.98
Weighted Average Cost Of Capital
Price
1.03
Beta
Diluted Shares Outstanding
8.98M
Costof Debt
4.15
Tax Rate
After Tax Cost Of Debt
0
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
0
Total Equity
9.25M
Total Capital
9.25M
Debt Weighting
0
Equity Weighting
100
Wacc
11.43
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
466.79k
1.24M
9M
3.31M
6.59T
10.49T
16.7T
26.59T
42.33T
67.39T
Ebitda
-27.63M
-36.32M
-19.79M
-11.79M
-11.12T
-10.49T
-16.7T
-26.59T
-42.33T
-67.39T
Ebit
-28.71M
-39.48M
-23.47M
-14.58M
-4.53M
-8.39T
-13.36T
-21.27T
-33.86T
-53.91T
Tax Rate
100
100
100
100
100
100
100
100
100
100
Ebiat
-28.53M
-39.47M
-23.46M
-14.59M
-4.55
-6.7T
-10.67T
-16.99T
-27.04T
-43.05T
Depreciation
1.08M
3.16M
3.68M
2.79M
-11.12T
4.72T
7.52T
11.97T
19.06T
30.34T
Receivables
1M
237
2.4M
1.03M
2.35T
4.06T
6.46T
10.28T
16.37T
26.06T
Inventories
-1M
-
-
-988.13k
-
-2.72T
-4.34T
-6.91T
-10.99T
-17.5T
Payable
2.94M
5.14M
1.1M
961k
1.07M
5.06T
8.06T
12.83T
20.42T
32.51T
Cap Ex
-10.43M
-3.13M
-4.95M
-
-
-5.35T
-8.52T
-13.56T
-21.58T
-34.36T
Ufcf
-34.94M
-37.23M
-31.17M
-9.57M
-13.47T
-1.25T
-9.46T
-15.06T
-23.97T
-38.16T
Wacc
11.43
11.43
11.43
11.43
11.43
Pv Ufcf
-1.12T
-7.62T
-10.88T
-15.55T
-22.21T
Sum Pv Ufcf
-57.38T
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
11.43
Free Cash Flow T1
-38.93T
Terminal Value
-412.66T
Present Terminal Value
-240.18T
Intrinsic Value
Enterprise Value
-297.56T
Net Debt
-19.19M
Equity Value
-297.56T
Diluted Shares Outstanding
8.98M
Equity Value Per Share
-33.14M
Projected DCF
-33135073 1%
